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Abstract
Background: Our study aim was to compare allogeneic cancellous bone (ACB) and synthetic or highly-processed
xenogeneic bone substitutes (SBS) in the treatment of skeletal defects in orthopedic surgery.
Methods: 232 patients treated for bony lesions with ACB (n = 116) or SBS (n = 116) within a 10-year time period
were included in this case–control study. Furthermore, both materials were seeded with human osteoblasts (hOB,
n = 10) and analyzed by histology, for viability (AlamarBlue®) and protein expression activity (Luminex®).
Results: The complication rate was 14.2 %, proportion of defects without bony healing 3.6 %; neither outcome
parameter differed comparing the intervention groups. Failed consolidation correlated with an increase in
complications (p < 0.03). The rate of complications was further highly significant in association with the location
of use (p < 0.001), but did not depend on age, ASA risk classification, BMI, smoking behavior or type of insurance.
However, those factors did significantly influence the bony healing rate (p < 0.02). Complication and consolidation
rates were independent of gender and the filling substances employed within the different locations. Histological
examination revealed similar bone structures, whereas cell remnants were apparent only in the allografts. Both
materials were biocompatible in-vitro, and seeded with human osteoblasts. The cells remained vital over the 3-week
culture period and produced microscopically typical bone matrix. We observed initially increased expression of
osteocalcin, osteopontin, and osteoprotegerin as well as leptin and adiponectin secretion declining after 1 week,
especially in the ACB group.
Conclusion: Although both investigated materials appeared to be similarly suitable for the treatment of skeletal lesions
in-vivo and in-vitro, outcome was decisively influenced by other factors such as the site of use or epidemiological
parameters.
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Background
The treatment of large bone defects caused by trauma, de-
generative or congenital diseases and tumor lesions is one
of the greatest challenges in current orthopedic research,
making the development of effective bone regeneration
therapies a major topic. Although the amount of available
autogenous cancellous bone is naturally limited, and graft
harvesting from the iliac crest leads to significant donor-
site morbidity [1], autogenous bone grafts combining
osteogenic, osteoconductive and osteoinductive properties
must be considered the gold standard for bone replace-
ment for now [2]. The osseous regeneration capacity is
limited in older patients especially, and donor site morbid-
ity increases [3]. The known disadvantages of autologous
bone grafting have prompted the search for alternatives.
The long-term clinical goal is to regenerate an adequate
amount of bony tissue with anatomical, physiological,
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three-dimensional morphology. In addition to bone appli-
cations, current bone regeneration strategies include cell-
based or stem cell-based treatments, the application of
bioactive factors such as BMP-2 and BMP-7, different
biologic or artificial scaffolds and various combinations
[2]. However, current and emerging therapies are still sig-
nificantly restricted. Several artificial bone materials have
recently been tested. Artificial bone grafts, most based on
tricalcium phosphate (TCP) or hydroxyapatite (compo-
nents of natural bone) usually only possess osteoconduc-
tive properties enabling adjacent osteoblasts to migrate
[4]. Synthetic bone grafts are an alternative to autologous
and allogeneic graft options, given their wide availability,
comparatively low cost, slow biodegradation, superior
strength in compression and the absence of risks such as
donor-site morbidity and viral transmission. However, be-
cause they are strictly osteoconductive, their biologic role
is limited, especially in fracture healing [5].
In the early 2000s more than 500,000 bone grafting pro-
cedures per year were carried out in the United States and
2.2 million worldwide in order to augment bone defects in
orthopedics or other fields as dentistry [6]. Allogenous bone
grafts are harvested from humans or human cadavers,
undergo sterile processing and are transplanted to a recipi-
ent. Depending on the preparation process, allografts
exhibit osteoconductive and sometimes osteoinductive
potential. Allogeneic transplants can be infectious [7, 8],
may trigger immunological reactions [9–11], and the
sterilization process prior to transplantation leads to the
loss of osteoinductive properties [12–14]. Recent studies by
Ghanaati et al. [11] and Fretwurst et al. [15] revealed the
presence of organic/cellular remnants in allografts and
xenogeneic bone blocks commercially available for dental
and orthopedic surgery that might induce an immune
response. As freezing alone is insufficient in safety terms
[16], terminal sterilization, usually irradiation, is carried out
as well. However, the incorporation of allografts is reduced
to approximately 40 % after irradiation [17, 18], compared
to 80–100 % in non-irradiated grafts [19–21]. The freezing
process also delays the vascularization of allografts after
implantation [22], which might be detrimental, as vascular-
ity has been identified as a central component influencing
bone healing and necessary to effective graft repair [2]. The
limited osteoinductive capacity of allografts presumably
plays a fundamental role in allograft failure due to fracture
or nonunion [14].
In contrast to adult hyaline cartilage, which does not
restore its native structure once damaged, the human
skeleton has a remarkable ability to regenerate after
injury. Nevertheless, the conditions for spontaneous
bone healing are not always ideal. Substantial bone loss
in case of trauma or tumor lesions often requires bone-
graft augmentation. Evidence of the effectiveness of graft
incorporation and fracture healing remains elusive [23, 24].
Most of the literature addresses medium and long-term
outcomes after revision arthroplasty [25]. In terms of bone
grafting in fracture therapy, the latest data merely focus on
certain anatomical locations [24, 26].
The aim of this study was to compare and determine the
clinical effectiveness of allogeneic cancellous bone grafts
(ACB) and synthetic or highly processed xenogeneic bone
substitutes (SBS) for treating bony defects in different sites
considering epidemiological and custom-designed parame-
ters. Our rationale for comparing these two groups was the
substantial differences described above, including the pre-
sumed presence of cell remnants in ACB in contrast to
SBS. Nevertheless, we hypothesized that there would be no
difference between ACB and SBS in their effectiveness in
bone regeneration or consolidation. To clarify possible dif-
ferences regarding biocompatibility and osteoconductivity,
in-vitro testing was additionally carried out. Our hypothesis
regarding the in-vitro experiments was that it is possible to
predict in-vivo differences.
Methods
The study is divided into a clinical and an experimental
part.
Patients
Within one decade, from 2001 to 2011, we identified 232
patients treated with ACB or SBS (117 female, 115 male;
mean age 59 ± 18 years) based on the documented OPS
code. The following SBS were used: BioOss® (Geistlich,
Wolhusen, Switzerland) in 41.4 %, and at clearly lower
percentages, respectively: Norian SRS® (Synthes) (8.6 %),
Chronos® (Synthes) (1.7 %), Atlantik® (Argomedical) (2.6 %),
Alaska® (Argomedical) (0.9 %), Endobone® (Biomet) (4.3 %),
Pyrost® (Stryker) (0.9 %), Nanostim® (Medtronic) (37.1 %),
Actifuse® (Baxter) (0.9 %), Tutobone® (Novomedics) (0.9 %)
and PerOssal® (Botiss) (0.9 %). The SBS group thus
contained various xenogenic or synthetic, commercially
available bone substitutes, which, according to the manu-
facturers’ information, had undergone multiple purification
processes and were supposed to be free of organic residues.
Commercially-available human allografts, freeze-dried can-
cellous bone from femoral heads and freeze-dried cancel-
lous cubes or blocks (DIZG, German Institute for Cell and
Tissue Replacement, Berlin, Germany) were used in the
ACB group. The study’s end points were defined as con-
solidation or treatment failure. We also determined the
occurrence of complications. Similar to trials following
the German Pharmaceuticals Act regulations, all compli-
cations were documented as adverse events. We investi-
gated the relationship between a given complication and
the use of a particular bone-graft material in both groups.
When in doubt, we presumed a correlation between the
complication and the use of bone graft, which was then
documented as an adverse event. Basically, complications
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were defined as the need for surgical revision/re-operation
or a patient’s death. Documented complications were:
death, re-operation, infection/wound infection, seroma,
pseudarthrosis, re-fracture, plate or screw fracture or loos-
ening, secondary dislocation, loss of reduction, necrosis of
the humeral head, cup/implant loosening, nerve palsy and
cyst recurrence. We ultimately enrolled 116 patients
treated with allografts and 116 patients treated with syn-
thetic or highly-processed bone grafts in this study.
To ensure better comparability of the various bone-graft
materials used, we defined influencing factors: besides
gender and age, clinical outcome was assessed in regard to
defect location, defect size, reason and type of application
(fracture or bone defect for other reasons (e.g., bone cysts,
osteochondritis dissecans, tumor); ACB or SBS), time to
consolidation, duration of hospital stay, kind of insurance,
BMI (body mass index), ASA (American Society of Anes-
thesiologists) risk classification, and smoking habits.
The study was approved by the Ethics Committee of the
University of Freiburg (registration number 10010/15). All
included individuals have declared their informed consent
for the retrospective analysis of their treatment data.
Experimental setup
To test their biocompatibility, the most frequently used
representatives of ACB and SBS were seeded with human
osteoblasts and cell viability and metabolic activity were
analyzed. The cells’ preparation protocols were approved
by the Ethics Committee of the University of Freiburg as
part of the ‘Tissue bank for research in the field of tissue
engineering’ project (GTE-2002) and the biobank ‘Osteo’
(AN-EK-FRBRG-135/14). Cancellous bone (DIZG, Berlin,
Germany) and BioOss®-Granula (Geistlich, Wolhusen,
Switzerland) in size of 3–4 mm were therefore used.
BioOss® (Geistlich, Wolhusen, Switzerland) is a natural,
nanocrystalline, carbonated hydroxyapatite of bovine ori-
gin. A patented multi-stage purification process prior to
gamma-sterilization should remove proteins and de-
activate viruses and other pathogens. The inorganic bone
matrix with its macro- and microporous structure provides
osteoconductive properties similar to human cancellous
bone. We used BioOss® in further in-vitro experiments in
the SBS group because of its frequent in-vivo application.
ACB and BioOss® were examined for any cells or cellular
remnants prior to colonization with hOB by histology.
Histologic processing
Histologic processing was done as described [15]. The
specimen was dehydrated in 100 % ethanol and subse-
quently infiltrated, embedded and polymerized in Tech-
novit 9100 (Heraeus Kulzer, Wehrheim, Germany)
according to the manufacturer’s instructions. After the
polymerization process, samples were cut into 500 μm
sections using a rotary diamond saw Secotom- 50 (Stuers,
Ballerup, Denmark). The sections were mounted onto
opac acrylic-slides (Maertin, Freiburg, Germany) and
ground to a final thickness of approximately 60 μm on a
rotating grinding plate (Stuers, Ballerup, Denmark). All
specimens were stained with azure II and pararosaniline
(Merck, Darmstadt, Germany).
Slides were imaged with an Axio Imager M1 microscope
equipped with a digital AxioCam HRc (Carl Zeiss, Göttin-
gen, Germany). The histologic sections were analyzed via
analySIS FIVE – software (Soft Imaging System, Münster,
Germany).
Isolation of osteoblasts
Femoral heads were obtained during hip arthroplasty
operations following femoral neck fractures. The mater-
ial used was taken following informed consent from
patients in accordance with the Ethics Committee of the
University of Freiburg as part of the ‘Tissue bank for
research in the field of tissue engineering’ project (GTE-
2002) and the biobank ‘Osteo’ (AN-EK-FRBRG-135/14).
The degree of osteoarthritis was evaluated on X-rays using
Croft’s modification of the Kellgren and Lawrence grading
system. Cells from patients with a Kellgren and Lawrence
Score ≤2 were used in our experiments. Post-surgery
human primary osteoblasts (hOB) were isolated within
8 h from cancellous bone by cell outgrowth from small
pieces, as described [27]. Human OBs were cultured and
expanded in medium 199 (Gibco, Carlsbad, CA), supple-
mented with 10 % FCS and 1 % penicillin-streptomycin at
37 °C and 5 % CO2. Human OBs from passage 1 or 2 were
used in all further experiments.
Cell seeding
Prior to application, we assessed cell viability, cytotoxicity
and apoptosis events as well as specific osteogenic charac-
teristics using ApoTox-Glo™ Triplex and AttoPhos® As-
says (Promega, Madison, WI, USA) showing vital (>90 %)
and typical osteoblasts. Similar amounts of BioOss® and
allogeneic cancellous bone (20–25 mg) were weighed into
50 ml falcons and moistened with medium 199, respect-
ively. Medium was discarded; bone grafts were seeded per
falcon at a density of 1 × 106 cells in 3 ml medium 199
and centrifuged at 1,200 rpm for 5 min. Cells were culti-
vated for 72 h at 37 °C and 5 % CO2 and then used in the
experiments.
AlamarBlue® - assay
The AlamarBlue®-Assay (AbD Serotec, Oxford, UK) is a
quantitative test to measure the cell proliferation and
viability of various human and animal cell lines, bacteria,
plant and fungi. When cells are alive, they maintain a re-
ducing environment within the cell’s cytosol. Resazurin,
the active ingredient in AlamarBlue® reagent, is a non-
toxic, cell permeable compound blue in color and highly
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fluorescent. Upon entering cells, resazurin is reduced to
resorufin, a red compound that is highly fluorescent.
Viable cells continuously convert resazurin to resorufin,
increasing the overall fluorescence and color of the
media surrounding cells [28].
Cells were cultivated for 1 week after isolation, followed
by incubation with medium 199 containing 10 % Alamar-
Blue® for another 24 h. Cells were centrifuged for 5 min at
1,200 rpm, and supernatant collected to assess the result-
ing fluorescence. Cell-seeded constructs were washed with
PBS, centrifuged and cultivated further in fresh medium.
Supernatants were aliquoted into microtiter plates and the
absorbance signal at 570 and 600 nm was detected on an
ELISA plate reader. The same assay was repeated after
3 weeks’ cultivation.
Milliplex® Human Bone Panel 1B
Milliplex® Human Bone Panel 1B Kit (Millipore AG, Zug,
Switzerland) is a magnetic bead-based antibody micro-
array founded upon the sandwich immunoassay principle.
The assay aims to quantify biomarkers that play a role in
bone metabolism. We investigated the following analytes:
osteocalcin (OC), osteopontin (OPN), osteoprotegerin
(OPG), leptin and adiponectin. The assay was performed
according to the manufacturers’ guidelines. Briefly, color-
code microspheres are coated with a specific capture anti-
body. After a test sample’s analyte is captured by the bead,
a biotinylated detection antibody is introduced and the
reaction mixture is then incubated with streptavidin-PE
conjugate, the reporter molecule, to complete the reaction
on each microsphere’s surface. The Luminex®-100 reader
is a system based on flow-cytometry principles. The reader
identifies the bead’s color-code as well as the bead
surface’s PE-fluorescence [29]. Analysis was performed
with the following adjustments: 50 μl probe, 50 beads per
set, gate 8,000–15,000, RP1 calibrator low PMT, time out
60 s. Protein was analyzed with the analytical software
provided by the manufacturers.
Scanning electron microscopy (SEM)
Scanning electron microscopy was performed after 1 and
after 3 weeks of cultivation to observe the cell loading and
growth patterns of hOBs on ACB and BioOss®. The cell-
seeded grafts were centrifuged, supernatant discarded, and
samples washed twice with PBS-buffer and fixed with
fixation buffer overnight. Specimens were then dehydrated
by rinsing them in an ascending ethanol-water mixture
(30, 50, 70, 80, 90, 99 %; 2 × 5 min at RT for each step)
and then rinsed in an ethanol-hexamethyldisalazin mix-
ture (EtOH:HMDS 2:1, 1:1, 1:2, HMDS; 2x5 min at RT for
each step). Finally, the samples were dried, sputtered with a
thin layer of gold (SC7620 Mini Sputter Coater, Gala
Instrumente, Bad Schwalbach, Germany), and examined
under a Phenom scanning electron microscope (PHENOM
Pure Desktop SEM, Phenom-World BV, Eindhoven,
Netherlands).
Statistical analysis
All values are expressed as mean ± standard deviation.
Normality was tested by the Kolmogorov-Smirnov test.
The paired t-Test was then used to assess differences
among normally-distributed mean values. In case of het-
erogeneous variances, the Aspin-Welch Test was applied.
Individual group mean scores were compared with the
Mann–Whitney U test. The statistical comparison of inci-
dences was done using the chi-square test. p < 0.05 was
considered significant in all tests. Statistical analysis was
carried out by the Statistical Package for the Social
Sciences (SPSS) software version 21 (SPSS Inc., Chicago,
USA).
Results
Characterization of patients treated with allografts
116 patients were treated with ACB. The gender ratio was
female/male (f/m) 62/54. The defect sites were distributed
as: humerus 10 patients, forearm 4 patients, hip/pelvis 48
patients, femur 27 patients, tibia 10 patients, foot 10
patients, spine 1 patient (Fig. 1). 45 patients were treated
for a fracture involving the loss of bone substance, 72
patients had a bony defect caused by other reasons such
as tumor or cyst lesions requiring surgery. We observed
bony consolidation of the defect in 104 patients, treatment
failure in 6 patients, 6 patients were dropouts. The average
time to consolidation was 3.93 ± 2.45 months; defect size
averaged 20.21 ± 21.00 cm2. Mean age in this group was
62.6 ± 19.6 at the time of surgery, mean BMI was 26.01 ±
5.15 kg/m2. 23 patients were current smokers, the mean
ASA risk classification was 2.31 ± 0.72 (Table 1). Compli-
cations occurred in 17 cases (14.7 %) (Table 2), 5 patients
passed away during the follow-up period. Duration of hos-
pital stay averaged 17.85 days. 90 patients had compulsory
health insurance (C), 21 private health insurance (P) and 6
patients were covered by an employer’s mutual insurance
association (E).
Characterization of patients treated with synthetic and
highly processed bone grafts
116 patients were treated with SBS. The f/m gender ratio
was 55/61. 41.4 % of the patients (n = 48) were treated
with BioOss® (Geistlich, Wolhusen, Switzerland). The defect
sites were distributed as: humerus 9 patients, forearm 10
patients, pelvis 3 patients, femur 3 patients, tibia 32
patients, foot 8 patients, spine 44 patients (Fig. 1). Bony
consolidation was observed in 107 patients, treatment fail-
ure in 2 patients and the healing state in 7 patients
remained unknown. The average time to consolidation was
3.16 ± 3.31 months; defect size averaged 5.75 ± 8.33 cm2. 52
patients were treated for a fracture, 64 patients were
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suffering from bony defects for other reasons. This group’s
mean age at the time of surgery in was 55.8 ± 16.3 years,
mean BMI was 26.99 ± 5.60 kg/m2. 36 patients were
current smokers, the mean ASA risk classification was 1.95
± 0.67 (Table 1). Complications occurred in 16 (13.8 %)
cases (Table 2), 1 patient passed away during follow-up.
Mean duration of hospital stay was 14.22 days. 82 patients
had compulsory health insurance (C), 19 private health in-
surance (P) and 11 patients were covered by an employer’s
mutual insurance association (E). To summarize: both
groups (4.1. and 4.2.) differed substantially in age, co-
morbidities and defect size, as indicated in Table 1.
Clinical results
The complication rate reached overall 14.2 %; Table 2
compares the examined parameters in the groups with or
without complication. The proportion of defects without
bony healing was 3.6 %; Table 3 compares the examined
parameters in the groups with or without healing. Failed
consolidation correlated with an increase in complications
(p < 0.03). The complication rate correlated very closely
with the site of use (p < 0.0002) (Fig. 2), but not with age,
gender, ASA risk classification, BMI, smoking behavior or
type of insurance (Table 2). However, these factors signifi-
cantly influenced the bony healing rate (p < 0.02) (Table 3).
Complication and consolidation rates were independent
of gender and the filling substances applied within the
different sites. We detected no significant differences in
the effectiveness of treating bony lesions with allografts
versus synthetic or highly-processed xenogeneic bone
grafts in various sites (Table 4). Higher complication rates
were documented in association with the treatment of
bony lesions in the humerus, tibia and the foot (Fig. 2). In
the vicinity of the humerus we documented screw
Fig. 1 Distribution of treatment location according to the bone substitute; all cases in each group (allogeneic cancellous bone [ACB] or synthetic
bone substitute [SBS]) amount to 100 %. Exact numbers are stated in the figure
Table 1 Epidemiological and characterizing parameters
Allogenic cancellous bone (ACB) N Synthetic bone substitutes (SBS) N P
Age 62.6 ± 19.6 116 55.8 ± 16.3 116 0.004a
Gender (f/m) 62/54 116 55/61 116 n.s.b
ASA 2.31 ± 0.72 116 1.95 ± 0.67 116 <0.0001c
Defect size 20.21 ± 21.00 114 5.75 ± 8.33 115 <0.0001a
BMI 26.01 ± 5.15 116 26.99 ± 5.60 116 n.s.a
Consolidation time (months) 3.93 ± 2.45 104 3.16 ± 3.31 107 n.s.d
Complication rate 17 (14.6 %) 116 16 (13.8 %) 116 n.s.b
Healing rate 104 (89.7 %) 116 107 (92.2 %) 116 n.s.b
Overview about the epidemiological and characterizing parameters comparing both intervention groups, f female, m male, ASA physical status according to the
American Society of Anesthesiologists, BMI body mass index, n.s. – not significant, at-Test, bχ2-Test, cU-Test (Mann und Whitney), dAspin-Welch-Test
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perforation, secondary loss of reduction, wound infection
and osteonecrosis of the humeral head. Complications in
the treatment of bony lesions of the proximal tibia were
mainly secondary loss of fracture reduction, deep infec-
tions and wound infections. Wound infections were the
main complication that occurred in the foot area. Consid-
ering the SBS group’s heterogeneity, further stratification
was analyzed comparing complication and consolidation
rates by discriminating between synthetic and highly-
processed xenogeneic materials within the SBS-group in
addition to the allografts (ACB) 116/61/55). Again, we
found no statistically significant differences (p for chi
square test >0.05 for all comparisons) in any endpoint
(complications: ACB 17/99, synthetic 7/54, xenogeneic 9/
46, consolidation failure: ACB 6/105, synthetic 0/58, xeno-
geneic 2/48, missing values 13).
In-vitro results
Histologic findings
Osteocytes, adipocytes and fibrocytes were detected in
ACB (Fig. 3a). No cells or cellular remnants were detect-
able on BioOss® prior to cell seeding with hOB. Osteocyte
lacunae were empty (Fig. 3b, arrows). In contrast to ACB,
no soft tissue was detected.
Alamar Blue®- assay
Results were analyzed by plotting absorbance versus
compound concentration, and we calculated the absolute
reduction. This value correlates with cell number and
metabolic activity. Human osteoblasts cultivated on
BioOss® revealed a reduction in resazurin after 1 week in
the AlamarBlue®-assay (53.1 ± 25.1 %); 41.8 ± 29.45 %
after 3 weeks. Osteoblasts cultivated on cancellous bone
(ACB) reduced resazurin by 35.2 ± 32.1 % after 1 week,
and 13.3 ± 9.8 % after 3 weeks of total resazurin applied.
Although the absolute resazurin reduction (cell number
and metabolic activity) decreased over time especially in
the allograft group (ACB), we detected no statistically
significant differences between the two intervention
groups and the two time points of cultivation (Fig. 4).
Milliplex Human Bone Panel 1B
We identified and quantified bone-specific biomarkers
in the supernatant after 1 and 3 weeks of cultivation.
Table 2 Influence on complications
Complication N No complication N
Age 63.52 ± 18.44 33 58.47 ± 18.24 199 n.s.a
Gender (f/m) 20/13 33 97/102 199 n.s.b
ASA 2.24 ± 0.66 33 2.11 ± 0.72 199 n.s.c
Defect size 10.98 ± 14.48 33 13.28 ± 17.95 196 n.s.a
BMI 26.79 ± 5.41 33 26.45 ± 5.39 199 n.s.a
Cancellous/Synthetic bone 17/16 33 100/99 199 n.s.b
Smoker/Non-Smoker 10/23 33 49/150 199 n.s.b
Insurance status W/C/P 23.5 %/13.4 %/12.2 % 32 76.5 %/86.6 %/87.8 % 198 n.s.b
Healing rate 7 (21.2 %) 33 1 (0.5 %) 186 <0.0001b
Consolidation time (months) 4.79 ± 4.39 26 3.36 ± 2.64 185 0.02a
Overview about the comparing parameters in patients with or without a complication, ffemale, m male, ASA physical status according to the American Society of
Anesthesiologists, BMI body mass index, n.s. not significant. W employers mutual insurance association, C compulsory health insurance fund, P private health
insurance fund. at-Test, bχ2-Test, cU-Test (Mann und Whitney)
Table 3 Influences on bone healing
Bony healing N No healing N P
Age 57.89 ± 18.01 211 72.51 ± 13.45 8 0.0025a
Gender (f/m) 102/109 211 6/2 8 n.s.b
ASA 2.09 ± 0.71 211 2.75 ± 0.46 8 0.014c
Defect size 12.90 ± 17.62 211 18.51 ± 20.54 8 n.s.a
BMI 26.42 ± 5.38 211 26.94 ± 4.19 8 n.s.a
Cancellous/Synthetic bone 104/107 211 6/2 8 n.s.b
Smoker/Non-Smoker 51/160 211 5/3 8 0.014b
Insurance status W/C/P 13/159/38 210 3/3/1 7 0.0012b
Overview about the comparing parameters in patients with or without bony consolidation, ffemale, m male, ASA physical status according to the American Society
of Anesthesiologists, BMI body mass index, n.s. not significant, W employers mutual insurance association, C compulsory health insurance fund, P private health
insurance fund. at-Test, bχ2-Test, cU-Test (Mann und Whitney)
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Osteocalcin (OC), osteopontin (OPN), osteoprotegerin
(OPG), leptin and adiponectin were detected and ana-
lyzed, revealing maintenance of the cells’ stable osteogenic
phenotype independent of the biomaterial employed.
Osteocalcin, a marker of bone anabolism, was detected
in all probes. Mean OC concentrations in cell culture
supernatants of human osteoblasts (hOB) cultivated on
BioOss® for 1 week were 160.2 ± 85.2 pg/ml; 62.9 ± 4.6 pg/
ml in the group of cancellous bone. Concentrations fell
after 3 weeks in both groups to 43.7 ± 6.1 pg/ml (BioOss®)
and 34.5 ± 3.7 pg/ml (ACB), respectively. The ACB group’s
concentrations decreased significantly from 1 to 3 weeks
(p = 0.002) (Fig. 5a, but there was no statistically signifi-
cant difference between the groups analyzing the respect-
ive time points.
Mean concentrations of osteopontin were 1,514.2 ±
883.9 pg/ml after 1 week in supernatants of osteoblasts
cultivated on BioOss®. Concentrations decreased after
3 weeks to 187.5 ± 70.1 pg/ml. Osteoblasts cultivated on
cancellous bone (ACB) showed mean concentrations of
185.2 ± 32.1 pg/ml after 1 week and 51.6 ± 14.8 pg/ml after
3 weeks of cultivation. The ACB group’s OPN concen-
trations dropped significantly from 1 week to 3 weeks
(p = 0.0045). OPN concentrations were lower on cancel-
lous bone after 1 (p = 0.050, n.s.) and after 3 weeks
compared to concentrations on BioOss® (p = 0.052, n.s.)
without reaching statistical significance (Fig. 5b).
Osteoprotegerin was secreted by human osteoblasts
seeded onto BioOss®; concentrations averaged 61.7 ±
19.4 pg/ml after 1 week and 73.3 ± 32.5 pg/ml after 3 weeks.
Osteoblasts seeded onto cancellous bone displayed concen-
trations of 29.7 ± 9.0 pg/ml after 1 week and of 10.6 ±
2.8 pg/ml after 3 weeks. OPG was expressed less in the
supernatant of osteoblasts seeded onto cancellous bone
when compared to BioOss® after 1 (p = 0.081, n.s.) and after
3 weeks (p = 0.039) (Fig. 5c).
We detected leptin after 1 week in the BioOss® group
at concentrations of 10.7 ± 2.9 pg/ml, after 3 weeks of
8.9 ± 1.99 pg/ml; concentrations of 11.9 ± 0.9 pg/ml and
4.1 ± 1.5 pg/ml were measured in the ACB group,
respectively. The ACB group’s decrease was significant
from 1 to 3 weeks (p = 0.002) (Fig. 5d), but there was no
Fig. 2 Frequency of complications according to the location where the various bone substitutes were applied; all patients in each group (complication or
no complication) amount to 100 %. Exact numbers are stated in the figure
Table 4 Bone healing and complications within different locations
Consolidation yes/no N P Complication yes/no N P
Cancellous Synthetic Cancellous Synthetic
Humerus 10/0 8/1 19 n.s.a 5/7 5/5 22 n.s.a
Forearm 4/0 10/0 14 n.s.a 0/4 1/10 15 n.s.a
Femur 24/3 3/0 30 n.s.a 5/22 0/3 30 n.s.a
Tibia 9/1 31/1 42 n.s.a 3/7 5/29 44 n.s.a
Spine 0/1 44/0 45 n.s.a 1/0 2/45 48 n.s.a
Pelvis 47/1 3/0 51 n.s.a 2/50 0/3 55 n.s.a
Foot 10/0 8/0 18 n.s.a 1/9 3/5 18 n.s.a
Number of complications and consolidation rates dependent on the group of applied bone substitutes, n.s. not significant, aχ2-Test
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statistically significant difference between the groups ana-
lyzing the respective time points.
Mean adiponectin concentration in the BioOss® group
after 1 week reached 130.3 ± 50.9 pg/ml, and 103.1 ±
21.9 pg/ml after 3 weeks. Mean concentration in the allo-
graft group after 1 week was 153.0 ± 25.3 pg/ml, and after
3 weeks 76.9 ± 19.2 pg/ml. The ACB group’s decrease
from 1 to 3 weeks was again significant (p = 0.04) (Fig. 5e),
but there was no statistically significant difference between
the groups analyzing the respective time points.
Whichever graft material was used, human osteoblasts
seeded onto ABC or SBS maintained their biochemical
characteristics. In short: the expression of osteogenic
biomarkers of human OB cultured on different graft
materials is similar and reveals a time-dependent regula-
tion pattern in-vitro.
Scanning electron microscopy (SEM)
Electron microscopy showed a homogeneous distribu-
tion pattern of osteoblasts seeded onto different bone
graft materials, good adhesion to the material and the
pericellular deposition of extracellular matrix. We also
noted that that after just one week, osseous matrix
adhered to the implants in both groups (Fig. 6a/b). After
a
b
Fig. 3 a/b: Histologic overview of allogeneic human cancellous bone (cryopreserved, caput femoris, DIZG) prior to use (a). Osteocytes and adipocytes are
visible (arrows). Newly-formed bone is stained dark magenta, older bone light magenta. Soft tissue (blue) with fibrocytes (arrow) is visible adjacent to the
bone trabeculae. Undecalcified ground sections, stained with azure II and pararosaniline, original magnification x 100 and x 400. The highly-processed
xenogeneic bone graft (Orthoss®/BioOss®) prior to use does not exhibit any cells or cell remnants (b). In contrast to allogeneic cancellous bone, no soft
tissue (blue) is detectable. Empty osteocyte lacunae are visible (arrows). Undecalcified ground sections, stained with azure II and pararosaniline, original
magnification x 50, x 100 and x 200
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3 weeks, intimate contact with osteoblasts embedded in
a mineralized, fibril-rich extracellular matrix was present
on both ACB and SBS (BioOss®). Although there were
no significant differences between the two groups in cell
viability or proliferation, semiquantative impression indi-
cated slightly more extensive osteoblast growth on the
BioOss® surface (Fig. 6c/d). We observed no interposi-
tioned interfacial layer or foreign-body reactions (not
expected) in any of the samples.
Discussion
Aim of this study was to compare the effectiveness of
treating bony lesions with allografts (ACB) versus syn-
thetic or highly-processed xenogeneic bone grafts (SBS) in
terms of patient-dependent factors and the various sites of
the bone defects. The key finding we made in this study is
the similar efficacy of ACB and SBS in the treatment of
skeletal lesions in-vivo and in-vitro, confirming our
hypothesis. Other factors such as the location of use and
epidemiological aspects have a greater impact on the clin-
ical outcome than does the type of bone graft.
We detected no significant differences between the ACB
and SBS groups either in their clinical findings or in-vitro
biocompatibility. The consolidation rate was influenced
significantly by epidemiological and patient-dependent
factors such as age, ASA risk classification, smoking habits
and type of insurance, but not by the bone-graft material
used. Interestingly, although the defect size differed sig-
nificantly between the groups, the consolidation rate was
not influenced by it. The complication rate in our study
correlated very significantly with defect location. Compli-
cation and consolidation rates did not display significant
differences between ACB and SBS within the same
location, however. Furthermore, the complication rate was
also not influenced significantly by the biomaterial group
used, but the bony-healing rate did correlate significantly
with the type of insurance, revealing worse outcomes in
patients covered by an employer’s or compulsory health
insurance in comparison to those with private coverage.
While patients cannot influence the injury site and/or
fracture or defect characteristics, bony healing may be
influenced by epidemiological and patient-dependent
factors, such as a healthy life style. Well-educated patients
are more likely to have private health insurance and show
potentially better compliance, factors that would explain
these clinical findings.
Current evidence-based treatment paradigms for bone
grafting in bony defects or fracture healing remain still
elusive and are frequently controversial [23, 24]. Most of
the available literature addresses medium- and long-term
outcomes after revision arthroplasty [25]. The latest data
on bone grafting in fracture care merely focuses on certain
anatomical locations [24, 26]. There is very little data on
bone substitutes and a paucity of randomized controlled
studies in particular, an observation also supported by a
Cochrane review from Board et al. concerning the com-
parison of processed versus fresh-frozen bone for impac-
tion bone grafting in revision hip arthroplasty. No
randomized controlled trial comparing the clinical use of
processed versus fresh-frozen bone in revision hip surgery
has been published. Surgeons’ choices of bone graft now-
adays are more apt to be based on personal preference
and the graft material’s availability than on evidence [23].
Our data do not contradict to this approach, because we
could show that complication rates after bone grafting of
the hip is associated with a high success rate independent
on the used material. In contrast, several randomized tri-




































Fig. 4 Cell viability of hOB cultured on either ACB or BioOss® was measured using the AlamarBlue® assay. Cells were vital during the 3-week
culture period independent of the biomaterial used. No significant differences appeared between the two intervention groups and various points
concerning cell viability and proliferation
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have been published. Approximately 1,400 products for
use as bone void fillers are available on the international
market [30]. Most of the trials compare the clinical effect-
iveness of allografts, synthetic/processed bone grafts or
ceramics with autologous bone grafting. Thalgott et al.
conducted a prospective, blind, single-site study to evalu-
ate the outcomes and fusion rates of anterior lumbar
interbody fusions with fresh-frozen or freeze-dried fem-
oral ring allograft as part of a circumferential fusion in 40





















































































































Fig. 5 a Osteocalcin (OC) was detected in all probes. Although we noted a tendency toward slightly better results in the BioOss®-group and after
1 week’s cultivation; differences were statistically significant only in the ACB group (allogeneic cancellous bone), decreasing from 1 to 3 weeks
(p = 0.002). b The same pattern is observed for osteopontin (OPN), which was detectable in all samples but revealed a tendency toward slightly
better results in the BioOss®-group and after 1 week of cultivation; differences were statistically significant in the ACB (allogeneic cancellous bone)
group only, decreasing from 1 to 3 weeks (p = 0.0045). c Osteoprotegerin (OPG) was also secreted by human osteoblasts seeded onto BioOss® or
allograft (ACB). Here again the tendency toward slightly better results in the first 1 week: OPG concentrations in the supernatant of cultivated
grafts were higher in the BioOss® group after 3 weeks (p = 0.039). d Leptin was detected in all probes. Comparing the different biomaterials
and time points: differences attained statistical significance in the ACB group only (allogeneic cancellous bone), decreasing from 1 to 3 weeks
(p = 0.002). e Adiponectin was detected in all probes. Comparing the different biomaterials and time points: differences attained statistical
significance in the ACB group only (allogeneic cancellous bone), decreasing from 1 to 3 weeks (p = 0.04)
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fusion levels [31]. Correlating with our data, smoking was
in this study strongly associated with pseudarthrosis
development. 58.3 % of the smokers who received freeze-
dried allografts and 16.7 % of the smokers who underwent
fresh-frozen allografts required revision for non-unions.
In contrast, only one non-smoker (7.1 %) required revision
for pseudarthrosis after a freeze-dried allograft and another
non-smoker after a fresh-frozen allograft. Those results
support our study findings and confirm the influence of
smoking on the consolidation rate. Suchomel et al. con-
ducted a prospective semi-randomized study comparing
allograft to iliac crest bone graft in 79 patients undergoing
A
SEM of human osteoblasts seeded 
on BioOss® after 1 week of 
cultivation producing a typical bone 
matrix structure (image 
magnification 795x and 1980x as 
indicated).
B
SEM of human osteoblasts seeded 
on cancellous bone (ACB) after 1 
week of cultivation, likewise 
showing embedded cells in a bone 
typical extracellular matrix (image 
magnification 555x and 1300x as 
indicated).
C
After 3 weeks of cultivation an 
extensive growth of the osteoblasts 
could be observed on the surface 
on BioOss® (image magnification 
600x and 2840x as indicated).
D
After 3 weeks of cultivation on 
cancellous bone (ACB) a broad 
cell growth on the surface and 
matrix deposition could be 
detected, even though in a smaller 
amount than in the BioOss® group 
(image magnification 1880x and 
4350x as indicated).
Fig. 6 a SEM of human osteoblasts seeded on BioOss® after 1 week’s cultivation producing a typical bone matrix structure (image magnification 795x
and 1980x as indicated). b SEM of human osteoblasts seeded on cancellous bone (ACB) after 1 week’s cultivation, likewise showing embedded cells in
bone-typical extracellular matrix (image magnification 555x and 1300x as indicated). c After 3 weeks of cultivation, extensive osteoblast growth is visible
on the BioOss®-surface (image magnification 600x and 2840x as indicated). d After 3 weeks of cultivation on cancellous bone (ACB), broad cell growth
on the surface and matrix deposition are visible, although to a lesser extent than in the BioOss® group (image magnification 1880x and 4350x
as indicated)
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one- or two-level anterior cervical discectomy and fusion,
detecting no difference in graft migration or collapse. They
noted a significantly slower fusion rate at 3 and 6 months
in the allograft group, which was no longer present at 1
and 2 years [32]. A possible explanation are the immuno-
logical consequences of the histologically shown cell rem-
nants that were found during our investigation. Several
other studies confirm good consolidation rates in the field
of spine fusion independent of the graft material [30, 33],
which would be in line with our finding that this anatom-
ical location provides a good biological environment for
graft integration. In their prospective, randomized study of
29 patients, McConnell et al. observed 100 % fusion rates
in anterior cervical discectomy and fusion with either coral-
line hydroxyapatite or iliac crest bone grafting. However,
the hydroxyapatite group displayed a significantly higher
rate of graft fragmentation and settling [30, 34]. Fischer et
al. recommend the use of ceramics in common spinal
fusions as osteoconductors, but not without employing
additional osteoinductive material [30]. In fact, a combin-
ation of autologous graft material and SBS was used in 44
out of 45 cases of bone grafting in the spinal area in our
study. Overall, good consolidation rates in the field of spine
fusion may result from the combination of the osteocon-
ductive properties of SBS and osteoinductive capacities of
autologous graft material. Furthermore, a usually ample
blood supply may support consolidation in spine fusion
independent of different osteoconductive graft materials.
Nevertheless, problems arise with the use of different graft
materials when consolidation is radiologically assessed. A
scintigraphic study of 12 patients comparing hydroxyapatite
grafts and iliac crest bone graft showed the same rate of
uptake until fusion. Therefore, the authors concluded that
the radiolucent line is not always a sign of pseudarthrosis in
patients treated with hydroxyapatite [35]. As long as the
fusion confirmation is based on X-ray or CT-scan, it is hard
to differentiate between the bone graft material itself and a
lack of bone ingrowth. Multiple studies on clinical out-
comes after posterolateral lumbar fusion using ceramics as
bone graft extender have reported good results. Hence,
Fischer et al. hypothesize that the radiographic findings rep-
resent new bone formation [30].
The challenges of post-interventional radiologic assess-
ment lead to the subject of bone grafting in fracture care.
Unlike autograft or allograft, the total radiographic dis-
appearance of hydroxyapatite is not to be expected, since
its incorporation is associated with osseous ingrowth and
slight marginal resorption. Hydroxyapatite possesses osteo-
conductive properties and serves as a scaffold, in contrast
to the complete remodeling that occurs with auto- and
allografts. Concerning bone grafting in fracture care,
current data basically focuses on certain anatomical
locations [24, 26]. Herrera et al. reported good clinical re-
sults in 17 patients after external fixation and cancellous
allografting with freeze-dried, irradiated cancellous bone in
unstable distal radius fractures. In all cases, bone-graft
incorporation was evident, non-union did not occur.
Incorporation was defined as the loss of allograft radioden-
sity and trabeculae crossing the fracture line [26]. A study
by Arora et al. evaluated complications following internal
fixation using a palmar 2.4 mm-locking compression plate
in unstable distal radius fractures, with most complica-
tions involving tendon irritation. Delayed fracture union
occurred in 3 patients, and 1 patient experienced intra-
operative intra-articular screw displacement [36]. Correl-
ating with the described excellent bone healing capacity of
the forearm, we detected no non-union after bone grafting
in the forearm in our study, and only one complication.
The risk of non-union is minimal in distal radius fractures.
Consequently, bone-graft substitutes are primarily used to
provide structural stability and fill larger bony defects
[37]. Furthermore, advances in plate design and technol-
ogy such as locking plates [38] reduce the field of applica-
tion for bone grafts in distal radius fractures. There is still
a lack of robust evidence concerning bone grafting in dis-
tal radius fractures. A Cochrane Database analysis of
randomized clinical trials concluded that there was insuffi-
cient evidence regarding functional outcomes and safety
in the use of bone grafts and substitutes to treat distal
radius fractures [39]. Bone quality, the size of the bony
defect, blood flow to the fracture site, and the method of
fixation/immobilization, as well as patient-dependent epi-
demiological factors all affect the healing process and
maintenance of fracture reduction. As shown by our data,
different anatomic locations entail varying levels of bone-
forming activity and stability. Therefore, a single study
validating the use of a bone-graft material in one location
may not predict its performance in another anatomic site.
Good clinical results concerning bone grafting in spine
surgery, hip-joint arthroplasty or its application in distal
radius fractures [25, 30, 39, 40] are in line with our results
from both groups of bone-graft materials in those
locations.
With tibial plateau fractures, restoration of the plateau
surface is a key treatment factor. Residual depression zones
in the weight-bearing area on the tibial plateau bear the risk
of axis deviation and posttraumatic osteoarthritis [41].
However, restoring the tibial-plateau anatomy often leaves
larger cancellous bone defects, especially when bone frag-
ments have become impacted within the soft metaphyseal
bone. Various bone-graft materials are available and have
been used to fill metaphyseal cancellous bone defects. Vari-
ous challenges exist, such as inferior mechanical properties,
donor-site morbidity in autografting, toxic and exothermic
reactions when using traditional polymethyl-methacrylate
cement, graft-material dislocation and custom-designed
challenges such as graft preshaping or the inappropriate ap-
plication form. Lobenhoffer et al. conducted a prospective
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study of 26 patients suffering from type B2, B3 and C3 frac-
tures of the tibial plateau using an injectable calcium phos-
phate bone cement. 2 patients presented partial secondary
loss of reduction, one of whom could not comply with
partial weight bearing [42]. Veitch et al. presented a study
of 6 patients treated with compaction morselized fresh-
frozen bone allograft in tibial-plateau fractures. Despite
their small cohort, the authors recommend the treatment
of tibial-plateau fractures with fresh-frozen allograft be-
cause of its good graft incorporation, good remodeling and
lower costs [24]. Several single-site studies addressing the
use of different bone-graft materials in tibial-plateau frac-
tures are available, but there is little data from controlled,
randomized studies of bone grafting in tibia-plateau frac-
tures. A current study protocol of Nusselt et al. is compar-
ing the treatment of fracture defects in tibial-plateau
fractures with a bioresorbable hydroxyapatite/calcium
sulphate cement (Cerament™ Bone Void Filler) and autolo-
gous bone grafting [43]. Correlating with the comparable
experiences of different material classes, we observed no
significant group differences in consolidation or complica-
tion rates in tibial-plateau fractures in our study. 76 % of
our study patients with a tibial-plafond fracture underwent
fracture treatment with SBS to prevent the donor-site
morbidity associated with autografting and potential im-
mune reactions after allografting for relatively smaller bone
defects. Only 2 failures of consolidation were documented,
whereas an 18 % complication rate in tibial-plateau fracture
therapy in both intervention groups was recorded. The
complications we observed are in line with the current
literature concerning tibial-plateau fractures, as they tend
to entail secondary loss of reduction and wound infections
[24, 44].
There is a paucity of evidence-based data on bone graft-
ing in humeral bone defects. Daugaard et al. conducted a
study in 20 canine proximal humerus, examining the
combined effect of parathyroid hormone and bone graft
on implant fixation [45]. Taehoon et al. evaluated the
effect of β-tricalcium phosphate and poly-L-lactide-co-
glycolide-co-epsiolon-caprolactone membrane in canine-
humerus defects, obtaining the expected results from the
osteoconductive material, leading to the original morphol-
ogy’s restoration. However, the new cortical bone was
thinner and less well organized than the adjacent intact
cortex, and the amount of new cancellous bone was also
sparse [46]. Studies in humans mainly focus on fracture
care, the anatomical characteristics of different fracture
locations, and frequent complications [47–50]. Südkamp
et al. conducted a prospective, multicenter, observation
study investigating the open reduction and internal fix-
ation of proximal humeral fractures employing a proximal
humerus locking plate; 34 % complications were registered
in 155 patients. 40 % of the complications were attribut-
able to problems of surgical technique, mostly the intra-
operative perforation of the humeral head by a screw.
Further complications included plate fracture (1.9 %), im-
pingement (2.6 %), pseudarthrosis (2.6 %), wound infection
(3.9 %), loss of reduction (7.1 %), and necrosis of the
humeral head (3.9 %) [51]. Although the general complica-
tion rate in our study cohort amounted to only 14.2 %, the
location-specific complication rate was 30.3 % for the hu-
merus. This higher proportion is in line with the findings of
Südkamp et al. and seen after fracture care of the proximal
humerus with a locking plate. A failure of consolidation in
the humerus only occurred in 1 of 19 patients (SBS),
whereas 10 complications occurred (5 in each group). Good
consolidation rates in both groups indicate that treatment
efficacy depends on other influencing factors (such as epi-
demiological aspects, as well as local factors such as blood
supply, bone quality, anatomical characteristics and mech-
anical demands) rather than on the bone-graft material, at
least when it merely provides osteoconductive properties.
Other bone-graft techniques in humeral fractures aim to
prevent known difficulties. Khmelnitskaya et al. described a
D.G. Lorich technique to treat 4-part proximal humerus
fractures using an intramedullary fibula strut graft as a
reduction aid and as a structural augmentation for screw
purchase in patients with poor bone quality. This technique
seems to avoid frequent problems in humeral-fracture care
such as screw penetration or hardware cut-out [47], but it
does not improve the already good consolidation rate.
BioOss® was most frequently used in the SBS group,
thus we decided to compare the in-vitro characteristics of
ACB and BioOss®. Allografts and highly-processed bovine
hydroxyapatite showed similar in-vitro osteoconductive
properties and similar biocompatibility. Human osteo-
blasts on both materials maintained their stable osteogenic
phenotype, resulting in the expression of similar amounts
of osseous marker proteins. SEM imaging demonstrated
good adherence of the osteoblasts on both materials. After
a 3-week culture, osteoblasts were organized as nodular
aggregations, and the amount of deposited extracellular
matrix was greater than that after 1 week’s cultivation.
SEM imaging demonstrated dense collagen nanofibers
deposited on the scaffold spread homogenously and cover-
ing the entire surface. Those findings concur with the
results of Sachar et al., who investigated osteoblasts gained
from mice calvaria on three-dimensional nanofibrous
gelatin scaffolds [52]. However, they noted an increase in
protein synthesis and greater cell density in 5-day cultures
compared to cultures lasting 14 days. We hypothesized
that the decrease in protein and hormone concentrations
in both our study groups may be caused by a limited
amount of medium substrates in the in-vitro cultures.
Another reason for the decreasing proliferation and pro-
tein synthesis in-vitro in our study might be the use of
human osteoblasts isolated from elderly patients who had
undergone hip-arthroplasty surgery following femoral
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neck fractures, whereas many other studies employed
murine osteoblasts [52, 53].
We examined the protein and hormone synthesis of
OPN, OC, OPG, leptin and adiponectin in osteoblasts on
ACB and SBS. Osteopontin, a glycoprotein also known as
bone sialoprotein I, is a linking protein that binds hy-
droxyapatite, and its cell-adhesion properties are required
for osteoclastogenesis. OPN is expressed during the early
stages of differentiation of osteoclast and osteoblast pro-
genitors. OPN and OC are considered the most sensitive
markers for bone-specific tissue formation [54, 55]. After
1 week of cultivation on BioOss®, we detected high levels
of OPN and OC, whereas the early marker OPN de-
creased especially after 3 weeks. OC levels on ACB fell
significantly after 3 weeks, indicating a lack of substrates
or a lower proportion of matrix-embedded cells on ACB.
Furthermore, diminished protein synthesis in osteoblasts
isolated from elderly patients is conceivable. OPG and
RANKL are known to be essential effectors for osteoclas-
togenesis [56–58]. OPG, a cytokine receptor and member
of the tumor necrosis factor receptor superfamily secreted
by osteoblasts, inhibits differentiation of the osteoclast
precursor into mature osteoclasts by attaching to RANKL
and inhibiting osteoclastogenesis [59]. An increasing level
of OPG on BioOss® from 1 to 3 weeks indicates an anabolic
condition, whereas OPG on cancellous bone was expressed
significantly less after 3 weeks. Luo et al. described the
interrelation of adiponectin and the RANKL/OPG axis on
bone metabolism. Adiponectin induces RANKL and in-
hibits OPG expression in human osteoblasts through the
AdipoR1/p38 MAPK pathway, inducing osteoclast forma-
tion [60]. The different dynamics in protein levels of adipo-
nectin and OPG on BioOss®, together with a rise in OPG
after 3 weeks and a falling level of adiponectin therefore
reveal anabolic bone metabolism on BioOss® after 3 weeks.
The adiponectin level on ACB rises, whereas OPG de-
creases, indicating a catabolic condition, which may be
supported by overall lower protein levels (OC, OPN) on
ACB in comparison to BioOss®. The role of leptin, a pluri-
potent hormone linked to human body fat regulation in
bone metabolism is controversial [61–63]. Reseland et al.
demonstrated leptin secretion of human osteoblasts, which
promotes osteoblastic cell growth and bone mineralization
via an autocrine and endocrine mechanism [64]. However,
the expression of leptin seems to be restricted to the
mineralization and/or osteocyte transition period during
hOB differentiation [65]. The nearly-constant leptin level of
hOB cultured on BioOss® from 1 to 3 weeks indicates the
ongoing mineralization phase, which is supported by SEM
findings showing ample matrix deposition, whereas a sig-
nificant decrease was observed in the leptin level on ACB
from 1 to 3 weeks. Significant differences between the
protein and hormone synthesis on ACB and SBS were only
detected in conjunction with particular parameters in a
temporal pattern. Nevertheless, hOB cultivated on BioOss®
tend to demonstrate more beneficial levels of bone-specific
markers. Sachar et al. emphasize the importance of three-
dimensional cell embedding of hOB concerning the expres-
sion of cell-adhesion proteins and of other osteogenic
marker genes [52]. Allografts obtained from older donors
may be inferior to SBS in terms of their osteoconductive
properties because of lower bone-mineral density. The
SEM analysis revealed a greater amount of osteoblasts on
SBS and a homogenously-distributed matrix deposition
enabling three-dimensional embedding of the cells. An-
other explanation for the slightly inferior protein synthesis
on ACB is the freeze-drying process and/or subsequent
irradiation that might cause alterations in the anorganic
structure. Organic or cellular remnants in the allograft
might trigger immune reactions or impaired growth and se-
cretion behavior of hOB despite the purging processes. Our
hypothesis that in-vitro studies may predict in-vivo data
could be confirmed; ACB and SBS had similar biocompati-
bility with osteoblasts and clinically equal applicability.
However, considering the importance of clinically influen-
cing factors, the informative and especially predictive value
of the in-vitro studies seems to be limited.
Although we identified no significant group differences
in the Alamar Blue® assay, a tendency towards a decrease
of cell numbers and metabolic activity, especially in the
ACB group, was seen. Despite, this demonstrates similar
in-vitro biocompatibility of ACB and SBS. The decreasing
cell number over time may be explained by the absent
blood supply, which more efficiently transports nutrients
and growth hormones compared to cell-culture-typical
diffusion, a phenomenon described by e.g., Kneser et al.
[66]. This would also explain the decline in osteogenic
marker production that was especially seen in the ACB
group after the first week.
The aim of this study was to compare and determine
the clinical effectiveness of allogeneic cancellous bone
grafts (ACB) and synthetic or highly-processed xenogeneic
bone substitutes (SBS) to treat bony defects in different
locations while considering epidemiological and custom-
designed parameters. We hypothesized that there would
be no difference between ACB and SBS in their effective-
ness to regenerate and consolidate bone, a hypothesis we
confirmed. Our study’s complication rate correlated highly
significantly with the site of the bone defect, but not with
the bone-graft material used.
We are aware of our study’s limitations. The SBS group
contains a heterogenous amount of different xenogenic
and synthetic bone-graft materials reflecting the clinical
routine and occasional personal preferences. Nevertheless,
the most important finding we made is the similar efficacy
of ACB and SBS in the treatment of skeletal lesions inde-
pendent of the graft material used. Other key factors such
as the location of use and epidemiological aspects are
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much more likely to influence clinical outcomes than is
the type of bone graft.
The main bone-grafting sites in our study were the
humerus, tibia and foot in both intervention groups, in line
with the usual complication rates in fracture care and
implying that the occurrence of complications is not closely
related to bone grafting. The consolidation rate, our other
study endpoint, is primarily and significantly influenced by
epidemiological factors, again not by the biomaterial ap-
plied. The in-vitro analysis comparing the different classes
of bone substitutes is limited to biocompatibility assays in
combination with measurements of factors defining an
osteogenic environment. Although SEM supplemented this,
the examination lacks other cell types as osteoclasts, osteo-
cytes or chondrocytes that are necessary in-vivo for the
natural bone turnover.
In allogeneic bone transplantation, the risk of microbio-
logical contamination, transmission of viruses, delayed
incorporation, and cellular and humoral immune reac-
tions must be taken into consideration [67]. There have
been many satisfactory clinical results reported following
the application of allo- and xenografts [68, 69]. Neverthe-
less, Reikeras et al. describe complications after using
deep-frozen allogeneic bone in 25 to 35 % of patients [70].
Sterilization and disinfection can reduce the immune
response and the risk of infection, but they have major
effects on the grafts’ mechanical and biological properties.
Shegarfi et al. suspect that major histocompatibility com-
plex peptide proteins from donor cells might survive the
freezing process, making them subject to targeting by
antigen-presenting cells after transplantation, thus trigger-
ing a long-term immune response [69]. Ghanaati et al.
recently published data about organic and cellular rem-
nants in allogenic and xenogenic bone blocks subjected to
patented processing techniques that may cause immune
reactions [11].
Due to the sterilization process prior to transplantation,
allografts usually only provide osteoconductive properties,
having lost their osteogenic capacity by purging from
organic matrix and cell components. Nevertheless, our
histologic findings confirm the existence of soft tissue as
well as osteocytes, adipocytes and fibrocytes in the ACB
graft. ACB’s high osteogenic capacity after the sterilization
process seems doubtful. Lower levels of protein and hor-
mone secretion on ACB in comparison to BioOss® may
even reflect immune-reactions processes or compromised
cell growth and cell metabolism due to effects on the
mechanical and biological properties of ACB.
Individual differences such as age and the co-morbidities
of our study’s osteoblast donors could have caused differ-
ences in growth characteristics, protein secretion levels and
matrix deposition without attaining significance. Defects in-
volving greater diameters and costs will probably present
limitations regarding the use of SBS. The risks associated
with microbiological contamination, virus transmission,
and cellular or humoral immune reactions can only be
reduced through continued research, in particular of xeno-
genic material.
Conclusion
Both the materials we investigated (ACB vs. SBS) dis-
played similar in-vivo efficacy in the treatment of skeletal
lesions. Other factors influencing the clinical outcome are
the location of use and epidemiological parameters. Both
materials were biocompatible in-vitro. We detected only
marginal differences in the levels of protein and hormone
secretion of hOBs cultivated on BioOss® or ACB.
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